Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 14, 2008

Valeant Pharmaceuticals Acquires DermaTech for $12.6M

  • Valeant Pharmaceuticals acquired DermaTech for approximately AU$19 million ($12.6 million).

    Earlier this year, under the direction of a new CEO, Valeant revised its business strategy to, among other things, build on its strengths in neurology and dermatology.  DermaTech specializes in the development, production, and distribution of products to address common dermatological conditions; its current annualized net sales total approximately $6.9 million.



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »